vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical
company engaged in the discovery and development of new orally
administered treatments for Alzheimer’s disease and diabetes, today
announced that the Company has been selected for oral and poster
presentations on its diabetes product candidates, TTP273 and TTP399 at
the Keystone Symposia on New Therapeutics for Diabetes and Obesity.
The symposia will take place from April 17 – 20, 2016 in La Jolla, CA.
TTP273
Oral Presentation Details:
-
Presentation Title: Oral Small Molecule GLP-1 Receptor (GLP-1R)
Agonists for Type 2 Diabetes (T2DM) with Negligible Nausea and Vomiting
-
Session Date: Wednesday, April 20, 2016
-
Session Time: 8:30 a.m. - 11:30 a.m. PDT
Poster Details:
-
Poster Title: Oral Small Molecule GLP-1 Receptor (GLP-1R)
Agonists for Type 2 Diabetes (T2DM) with Negligible Nausea and Vomiting
-
Poster Number: 1025
-
Poster Session: 1
-
Session Date: Monday, April 18, 2016
-
Session Time: 11:45 a.m. - 10:00 p.m. PDT
TTP399
Poster Details:
-
Poster Title: The Importance of Tissue Selectivity and
Preservation of the Physiological Regulation when Targeting Key
Metabolic Regulators as Glucokinase
-
Poster Number: 2040
-
Poster Session: 2
-
Session Date: Tuesday, April 19, 2016
-
Session Time: 11:30 a.m. - 10:00 p.m. PDT
A copy of the posters will be made available in the News
& Events section of the Company’s website
following the presentations.
About Type 2 Diabetes
Type 2 diabetes is the body’s inability to properly use insulin to
control sugar in the bloodstream. It is the most common type of diabetes
(representing 90 to 95% of diabetes patients), imposing a growing burden
on healthcare systems globally. The goal of maintaining A1c levels below
7.0% is elusive for patients with this life-long disease. In addition to
unregulated glucose, diabetics commonly have a variety of
co-morbidities, including heart disease, stroke, high blood pressure,
blindness, kidney disease, amputations, dental disease, and central and
peripheral nervous system impairment.
About vTv Therapeutics Inc.
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company
engaged in the discovery and development of orally administered small
molecule drug candidates to fill significant unmet medical needs. vTv
has a pipeline of clinical drug candidates led by programs for the
treatment of Alzheimer’s disease and Type 2 diabetes as well as
treatment of inflammatory disorders and the prevention of muscle
weakness.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160412005313/en/
Copyright Business Wire 2016